Cedric Moreau

    Partner, Crossover Strategy

    Cedric joined us in June 2018, bringing his 18 years of experience in life sciences investment banking. He is a partner on the Crossover team.

    Cedric joined from Oddo BHF where he was managing director and head of healthcare in the corporate finance department. In 2017, Oddo BHF was the top ranked firm for European biotech equity capital market deals.

    Prior to this, he was director at Bryan Garnier & Co where he completed several sizable cross-border transactions, including Galapagos, DBV, Ablynx, and Celyad. In total, he has managed more than 2 billion euros in European healthcare transactions.

    Cedric brings to the Crossover team his transactional expertise in the biopharma industry, as well as an extensive network of key opinion leaders, bankers and lawyers.

    Cedric was well known to the Sofinnova team before he came onboard, having executed several mandates for portfolio companies.

    He said the Sofinnova Crossover team was taking a different approach compared with crossover transactions in the U.S., which typically involve investing just ahead of a company’s IPO.

    "We are more like late-stage VC investors," he said. "It's really the stage of maturity of the company that is important for us. Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept," then help them get ready for what comes next — usually a listing on the Nasdaq, and/or a deal with a major pharma or healthcare company.

    Before his corporate finance career, Cedric spent 10 years as a healthcare equity analyst, and was several times EXTEL top ranked (awarded for both individual and team performances) at Natixis and Fortis. He was in charge of coverage of listed biotech and pharma companies.

    Cedric holds a Master’s in Economics and post-graduate diploma in Finance and Taxation (Sorbonne) and diploma from the Société Française des Analystes Financiers (SFAF).

    "Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept."

    Sectors

    Biopharmaceuticals & Medical Devices

    Related companies

    Welcome to our new website – a fresh look that represents a new SofinnovaFind out more